window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-KF8FWV2XRD'); .grecaptcha-badge { display: none !important; } .page-id-1441 .grecaptcha-badge { display: block !important; }

COVID-associated pulmonary Aspergillosis – definitions for an emerging clinical syndrome

Reviewed by Hannah Imlay, MD, MS, University of Utah 

In response to multiple reports of COVID-associated pulmonary Aspergillosis (CAPA), a consensus statement has been prepared that defines proven, probable, and possible CAPA for the purposes of clinical care and clinical research, endorsed by multiple mycological societies. These guidelines will help establish a case definition for surveillance and incidence of cases as well as for future clinical research. Management guidelines are also included: voriconazole and isavuconazole are recommended as options for first-line treatment, with a tentative recommended duration of 6-12 weeks of therapy. 


Koehler P, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 Jun;21(6): e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14. PMID: 33333012; PMCID: PMC7833078. 

We use cookies to help improve your experience
(function(){var s = document.createElement("script");s.setAttribute("data-account","YPuz36iLRc");s.setAttribute("src","");document.body.appendChild(s);})();Enable JavaScript to ensure website accessibility